Virios Therapeutics, Inc. - VIRI STOCK NEWS

Welcome to our dedicated page for Virios Therapeutics news (Ticker: VIRI), a resource for investors and traders seeking the latest updates and insights on Virios Therapeutics stock.

Virios Therapeutics, Inc. (VIRI) is a development-stage biotechnology company dedicated to advancing novel antiviral therapies aimed at treating diseases associated with viral-triggered abnormal immune responses, such as fibromyalgia (FM) and Long-COVID (LC). With a focus on innovation and patient care, Virios Therapeutics is working on two main product candidates, IMC-1 and IMC-2.

IMC-1 is designed to synergistically suppress the activation and replication of herpesvirus, specifically targeting the Epstein-Barr virus (herpesvirus HHV-4). This approach aims to alleviate symptoms by addressing the underlying viral triggers of immune response abnormalities. IMC-2, a combination of valacyclovir and celecoxib, is another promising candidate in their pipeline.

Virios Therapeutics is committed to advancing their research and development efforts to bring these groundbreaking therapies to market. The company's headquarters is located at 1837 Commons North Drive, Tuscaloosa, Alabama, United States. Their team, led by Chairman and CEO Greg Duncan, is dedicated to addressing unmet medical needs with innovative solutions.

The latest updates from Virios Therapeutics reflect their ongoing progress in clinical trials and strategic partnerships. For more information, investors and interested parties can contact their Investor Relations team at IR@Virios.com.

02/29/2024 09:15 AM

News

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary

Virios Therapeutics, Inc. (VIRI) announced financial results for Q4 and full year 2023, focusing on developing antiviral therapies for fibromyalgia and Long-COVID. Key highlights include FDA communication on IMC-2 Phase 2, upcoming clinical data on valacyclovir/celecoxib for LC, and Phase 2 program initiation in LC. Financially, R&D expenses decreased significantly, leading to a reduced net loss compared to the previous year.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.37%

Tags

02/28/2024 09:15 AM

News

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Rhea-AI Summary

Virios Therapeutics, Inc. (VIRI) issues a Shareholder Letter highlighting progress and key milestones in 2024, including plans for a special shareholder meeting to approve a reverse stock split.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.26%

Tags

01/22/2024 09:00 AM

News

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Rhea-AI Summary

Virios Therapeutics, Inc. (VIRI) plans to advance IMC-2 as a treatment for Long-COVID symptoms, targeting the initiation of a Phase 2 program in the second half of 2024, with data expected in 2025. The company aims to address the unmet medical need associated with Long-COVID symptoms and is funding a placebo-controlled 12-week study of the valacyclovir/celecoxib combination in up to 60 Long-COVID patients. The company has also received input from the FDA on development requirements and key endpoints associated with advancing IMC-2 into Phase 2 development. Virios is preparing for the initiation of a Phase 2 clinical program and expects to provide an update on potential partnership developments later this quarter.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-40.32%

Tags

01/02/2024 07:05 AM

News

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Rhea-AI Summary

Virios Therapeutics, Inc. (Nasdaq: VIRI) has received feedback from the FDA on advancing IMC-2 as a treatment for Long-COVID (LC) illness. The FDA agreed to use fatigue as the primary endpoint and orthostatic intolerance as a key secondary endpoint to assess the effectiveness of IMC-2. Virios is exploring options to advance the IMC-2 LC Phase 2 research program, with the potential to be one of the first approved treatments specifically for LC.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.22%

Tags

11/13/2023 07:05 AM

News

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary

Virios Therapeutics, Inc. (Nasdaq: VIRI) Announces Q3 Financial Results and Milestones - Virios Therapeutics, a biotech company, reported Q3 financial results and upcoming milestones. Key highlights include FDA guidance for Phase 3 development of IMC-1 to treat fibromyalgia, submission of briefing materials for IMC-2 as a Long-COVID treatment, and filing for new IP protection for IMC-2. The company also expects capital to support operations into Q3 of 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-10.58%

Tags

11/06/2023 07:05 AM

News

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Rhea-AI Summary

Virios Therapeutics, Inc. will report its third quarter 2023 financial results on November 13, 2023. The company focuses on developing antiviral therapies for chronic diseases, including fibromyalgia and Long-COVID. A webcast and conference call will be held to discuss the results and provide a corporate update.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

6.4%

Tags

10/12/2023 07:05 AM

News

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

Rhea-AI Summary

Virios Therapeutics to present at ThinkEquity Conference

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.39%

Tags

09/18/2023 07:05 AM

News

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Rhea-AI Summary

Virios Therapeutics terminates Sales Agreement, focusing on operational priorities

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.92%

Tags

09/12/2023 07:05 AM

News

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

Rhea-AI Summary

Virios Therapeutics to present at SHARE™️ Series Monday Management Update for investors on September 18, 2023

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.16%

Tags

08/14/2023 07:05 AM

News

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

Rhea-AI Summary

Virios Therapeutics halts sales under Capital on Demand Sales Agreement with JonesTrading due to market conditions and investor sentiment.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

18.47%

Tags

FAQ

What is the current stock price of Virios Therapeutics (VIRI)?

The current stock price of Virios Therapeutics (VIRI) is $0.155 as of October 9, 2024.

What is the market cap of Virios Therapeutics (VIRI)?

The market cap of Virios Therapeutics (VIRI) is approximately 4.3M.

What does Virios Therapeutics specialize in?

Virios Therapeutics specializes in developing novel antiviral therapies to treat diseases associated with viral-triggered abnormal immune responses.

What are the main product candidates of Virios Therapeutics?

The main product candidates of Virios Therapeutics are IMC-1 and IMC-2, designed to treat conditions like fibromyalgia and Long-COVID.

Where is Virios Therapeutics headquartered?

Virios Therapeutics is headquartered at 1837 Commons North Drive, Tuscaloosa, Alabama, United States.

Who is the CEO of Virios Therapeutics?

The CEO of Virios Therapeutics is Greg Duncan.

How can I contact Virios Therapeutics for investor relations?

You can contact Virios Therapeutics for investor relations at IR@Virios.com.

What is IMC-1 designed to target?

IMC-1 is designed to synergistically suppress the activation and replication of herpesvirus, specifically the Epstein-Barr virus.

What diseases are Virios Therapeutics targeting with their therapies?

Virios Therapeutics is targeting diseases like fibromyalgia (FM) and Long-COVID (LC) with their antiviral therapies.

What does IMC-2 consist of?

IMC-2 consists of a combination of valacyclovir and celecoxib.

Is Virios Therapeutics currently conducting clinical trials?

Yes, Virios Therapeutics is actively conducting clinical trials to advance their product candidates.

How does Virios Therapeutics approach the treatment of fibromyalgia and Long-COVID?

Virios Therapeutics approaches the treatment of fibromyalgia and Long-COVID by targeting viral triggers of abnormal immune responses with their antiviral therapies.